Global Alzheimer Drugs Market - 2023-2030

Global Alzheimer Drugs Market - 2023-2030

The Global Alzheimer Drugs Market reached US$ 3.97 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 7.7 billion by 2030. The global alzheimer drugs market is expected to exhibit a CAGR of 8.7% during the forecast period 2023-2030.

The global market for Alzheimer's medications is expanding due to factors including the increasing prevalence of chronic diseases, including dementia, the growing size of the therapeutic pipeline, expenditures in biomarkers for diagnosis and drug development, and the creation of more sophisticated diagnostics for early detection.

The Alzheimer drugs market's drug type scope comprises Alzheimer drugs like donepezil, galantamine, rivastigmine, memantine and others, which has increased the market share for Alzheimer drugs type. These medications could lessen or regulate some behavioral and cognitive issues. Alzheimer’s drugs developments and upcoming medical approvals across countries are also creating a positive outlook for market growth.

Market Dynamics

Use of Biomarkers in Drug Development and Large Pipeline Drive the Growth of the Alzheimer Drugs Market.

The risk involved in creating medication is high, and biomarkers present a practical means of reducing the risk and enhancing technical success. The understanding of Alzheimer is rapidly developing, and important biological events are now being identified. Biomarkers that can be seen by brain imaging, in the blood or in the cerebrospinal fluid (CSF) may occasionally accompany these occurrences.

By utilizing these biomarkers to improve the drug development process, it may be possible to reduce the risk associated with the creation of Alzheimer therapies. As a result, the market for Alzheimer’s pharmaceuticals is being driven by the increasing significance of biomarkers in developing AD therapies.

Growing Research and Development and Rising Prevalence of Alzheimer Creates Lucrative Opportunities for Manufacturers.

Due to key players' significant investments in research and development capabilities for cutting-edge technical improvements, there is a developing market opportunity. Another trend influencing the market is the growing demand for Alzheimer treatment. According to the World Alzheimer Report, there are currently 50 million people living with Alzheimer’s disease or related dementia, and by 2050, that number is expected to rise to 152 million.

Additionally, the FDA has authorized the use of two pharmacological classes, cholinesterase inhibitors (Aricept, Exelon, Razadyne), and memantine (Namenda), to treat the cognitive side effects of Alzheimer’s disease, such as memory loss, disorientation, and problems with thinking and reasoning. With more clinical trials being conducted for the diagnosis and treatment of Alzheimer’s, the market will rise as a result.

High failure Rates of Late-Stage Drugs will Hamper the Growth of the Market

The global marketplace for Alzheimer’s drugs, however, may be constrained over the projected period due to the prohibitive prices of advanced medications, the inability of exploratory candidates during the latter stages, and the low level of knowledge of Alzheimer’s disease in poor countries.

For instance, in November 20222, results from the GRADUATE I and II Phase III studies investigating gantenerumab in patients with mild cognitive impairment (MCI) owing to Alzheimer’s and mild Alzheimer’s dementia, generally known as early Alzheimer’s disease, were released by Genentech, a member of the Roche Group. The research' main goal of decreasing clinical decline was not achieved.

COVID-19 Impact Analysis

The COVID-19 Analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to Pricing Dynamics (Including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply due to trading restrictions, lockdown, and afterward issues), Government Initiatives (Initiatives to reactivate a market, industry, or sector by Government Bodies), and Manufacturers Strategic Initiatives.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global alzheimer drugs market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global alzheimer drugs market growth over the forecast period.

Segment Analysis

The Global Alzheimer Drugs Market is segmented based on drug type, distribution channel and region.

Hospital Pharmacy from the Distribution Channel Segment Accounts for 40.1% of Market Share. Owing to Rising Hospital Admissions

The goal of hospital pharmacy is to constantly maintain and improve patient medication administration to the greatest levels imaginable. Controlling the usage of pharmaceuticals in hospitals and other medical facilities is the main responsibility of hospital pharmacies. One of the goals is to enhance patient outcomes through the prescription, procurement, distribution, management, and review of medications.

Hospital pharmacies will see an increase in demand thanks to benefits including teaching patients how to take their prescriptions, giving them in an emergency, and aiding with specialized medical treatment, like for cancer patients.

If necessary, the hospital pharmacy can assist with modifying dosages or altering drugs. Finding medicine formulations that the patient can use (such as injections, suppositories, and nasal sprays), and making sure the container can be read and opened with ease. identifying potential health issues unrelated to dementia. Hence above-mentioned factors prove that hospital pharmacies will be the largest market shareholder.

Geographical Analysis

North America accounted for approximately 39.2% of the market share due to major players’ strong presence and increasing technological advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for Alzheimer drugs for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of Alzheimer drugs, increasing demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand of Alzheimer drugs applications. Rising new product launches for using in patients with dementia or Alzheimer will drive the market growth.

Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of treatment approaches for Alzheimer such as biomarkers, leading to the expansion of the market in this region. These factors shows the dominance of North America.

Competitive Landscape

The major global players in the alzheimer drugs market include F. Hoffmann-La Roche, Merck & Co., Novartis AG, Pfizer Inc., Eli Lily and Co., Biogen Inc., Johnson & Johnson, AbbVie, Siemens Healthineers and Lupin among others.

Why Purchase the Report?
• To visualize the Global Alzheimer Drugs Market segmentation based on drugs type, distribution channel and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Alzheimer drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Alzheimer Drugs Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies